Startseite Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development

  • Hitomi Asazawa , Yoshihiro Kamada , Yuri Takeda , Shinji Takamatsu , Shinichiro Shinzaki , Youkoku Kim , Riichiro Nezu , Noriyoshi Kuzushita , Eiji Mita , Michio Kato und Eiji Miyoshi EMAIL logo
Veröffentlicht/Copyright: 23. Juli 2014
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 53 Heft 1

Abstract

Background: Fucosylation is one of the most important glycosylation events involved in cancer and inflammation. We previously developed a lectin antibody ELISA kit to measure fucosylated haptoglobin (Fuc-Hpt), which we identified as a novel cancer biomarker. In this study, we investigated Fuc-Hpt as a biomarker in chronic liver diseases, especially in hepatocellular carcinoma (HCC).

Methods: We measured serum Fuc-Hpt levels using our ELISA kit in 318 patients with chronic liver diseases, including 145 chronic hepatitis (CH) patients, 81 liver cirrhosis (LC) patients, and 92 HCC patients. During a long-term follow-up period of 7 years (1996–2003), Fuc-Hpt levels were measured at three different time points in 19 HCC patients. Serum Fuc-Hpt levels were also examined with a short-term follow-up period of 3 years (2009–2012) in 13 HCC patients.

Results: Fuc-Hpt levels increased with liver disease progression. Patients with LC and HCC showed significantly increased Fuc-Hpt levels in comparison to CH patients or healthy volunteers. Fuc-Hpt levels tended to be higher in HCC patients than in LC patients. Fuc-Hpt was better than α-fetoprotein (AFP) and AFP-L3 for predicting HCC [diagnosed by computed tomography (CT) or ultrasound] in LC patients with long-term follow-up. More than 80% of LC patients with long-term follow-up showed increased Fuc-Hpt during hepatocarcinogenesis, and 38% of early-stage HCC patients with short-term follow-up showed a gradual increase in Fuc-Hpt before imaging diagnosis.

Conclusions: These results suggest that Fuc-Hpt is a novel and potentially useful biomarker for predicting liver disease progression and HCC development.

Keywords: α-fetoprotein (AFP); fucosylation; lectin antibody ELISA kit; protein induced by vitamin K antagonist II (PIVKA-II)
Corresponding author: Eiji Miyoshi, MD, PhD, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7, Yamada-oka, Suita, Osaka 565-0871, Japan, Phone/Fax: +81 6 68792590, E-mail:
aHitomi Asazawa and Yoshihiro Kamada contributed equally to this study.

Acknowledgments

Financial support: This study was supported by a Grant-in-Aid for Scientific Research (A), No. 21249038 from the Japan Society for the Promotion of Science and performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, and Science.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial Support: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725–9.10.1093/jb/mvn011Suche in Google Scholar PubMed

2. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:1914–21.10.1158/1055-9965.EPI-08-0980Suche in Google Scholar PubMed PubMed Central

3. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004;101:2825–36.10.1002/cncr.20713Suche in Google Scholar PubMed

4. Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010;56:823–31.10.1373/clinchem.2009.139295Suche in Google Scholar PubMed

5. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420–32.10.1002/hep.1840120625Suche in Google Scholar PubMed

6. Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14:15–20.10.1111/j.1365-3083.1981.tb00179.xSuche in Google Scholar PubMed

7. Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci 1983;417:61–8.10.1111/j.1749-6632.1983.tb32849.xSuche in Google Scholar PubMed

8. Aoyagi Y. Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 1995;12:194–9.10.1007/BF00731319Suche in Google Scholar PubMed

9. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110–8.10.1053/j.gastro.2009.04.005Suche in Google Scholar PubMed PubMed Central

10. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803–8.10.1002/ijc.21728Suche in Google Scholar PubMed

11. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122:2301–9.10.1002/ijc.23364Suche in Google Scholar PubMed

12. Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012;118:3036–43.10.1002/cncr.26490Suche in Google Scholar PubMed

13. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008;377:792–6.10.1016/j.bbrc.2008.10.061Suche in Google Scholar PubMed

14. Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med 2010;48:505–12.10.1515/CCLM.2010.095Suche in Google Scholar PubMed

15. Kormoczi GF, Saemann MD, Buchta C, Peck-Radosavljevic M, Mayr WR, Schwartz DW, et al. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest 2006;36: 202–9.10.1111/j.1365-2362.2006.01617.xSuche in Google Scholar PubMed

16. Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, et al. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013;417:48–53.10.1016/j.cca.2012.12.014Suche in Google Scholar PubMed

17. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306–11.10.1016/j.ab.2009.02.030Suche in Google Scholar PubMed

18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.10.1002/hep.510240201Suche in Google Scholar PubMed

19. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797–806.10.1074/jbc.M605697200Suche in Google Scholar PubMed

20. Nakagawa T, Takeishi S, Kameyama A, Yagi H, Yoshioka T, Moriwaki K, et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J Proteome Res 2010;9:4888–96.10.1021/pr100414rSuche in Google Scholar PubMed

Supplemental Material

The online version of this article (DOI: 10.1515/cclm-2014-0427) offers supplementary material, available to authorized users.

Received: 2014-4-19
Accepted: 2014-6-30
Published Online: 2014-7-23
Published in Print: 2015-1-1

©2015 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Harmonisation of specialist training and continuing professional development in laboratory medicine: a long but necessary journey
  4. Reviews
  5. Laboratory medicine in the European Union
  6. Role of leptin in female reproduction
  7. Mini Review
  8. Interrelatedness between C-reactive protein and oxidized low-density lipoprotein
  9. General Clinical Chemistry and Laboratory Medicine
  10. Comparison of approaches and measurement of continuing professional development for specialists in laboratory medicine within four European countries
  11. Point-of-care urine albumin in general practice offices: effect of participation in an external quality assurance scheme
  12. Triple positive antiphospholipid antibody profile in outpatients with tests for lupus anticoagulants
  13. Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins
  14. Proteolysis is a confounding factor in the interpretation of faecal calprotectin
  15. Urinary neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic kidney disease patients
  16. Cancer Diagnostics
  17. Quantification of adult T-cell leukemia/lymphoma cells using simple four-color flow cytometry
  18. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development
  19. Cardiovascular Diseases
  20. Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease
  21. S100B concentrations increase perioperatively in jugular vein blood despite limited metabolic and inflammatory response to clinically uneventful carotid endarterectomy
  22. Long-term biological variability of galectin-3 after heart transplantation
  23. Diabetes
  24. Evaluation of a next generation direct whole blood enzymatic assay for hemoglobin A1c on the ARCHITECT c8000 chemistry system
  25. The 13C-glucose breath test is a valid non-invasive screening tool to identify metabolic syndrome in adolescents
  26. Comparison of a direct enzymatic assay and polyacrylamide tube gel electrophoresis for measurement of small, dense low-density lipoprotein cholesterol
  27. Letters to the Editor
  28. Comparison of Abbott Architect high-sensitivity troponin I in Rapid Serum Tubes and plasma
  29. Can EDTA, EDTA-fluoride, and buffered citrate tubes be used for measurement of HbA1c on the Bio-Rad D10?
  30. How to reduce EDTA contamination in laboratory specimens: a Tunisian experience
  31. Does mean platelet volume share any relationship with biochemical and hematological parameters?
  32. Association of retrospective markers of glycemia and the use of continuous glucose monitoring in white adults with type 2 diabetes mellitus – a preliminary report
  33. Operative performances and efficiency for infectious disease testing of two immunochemistry analyzers – Abbott ARCHITECT i2000SR and DiaSorin Liaison XL
https://doi.org/10.1515/cclm-2014-0427
Schlagwörter für diesen Artikel
α-fetoprotein (AFP); fucosylation; lectin antibody ELISA kit; protein induced by vitamin K antagonist II (PIVKA-II)

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Harmonisation of specialist training and continuing professional development in laboratory medicine: a long but necessary journey
  4. Reviews
  5. Laboratory medicine in the European Union
  6. Role of leptin in female reproduction
  7. Mini Review
  8. Interrelatedness between C-reactive protein and oxidized low-density lipoprotein
  9. General Clinical Chemistry and Laboratory Medicine
  10. Comparison of approaches and measurement of continuing professional development for specialists in laboratory medicine within four European countries
  11. Point-of-care urine albumin in general practice offices: effect of participation in an external quality assurance scheme
  12. Triple positive antiphospholipid antibody profile in outpatients with tests for lupus anticoagulants
  13. Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins
  14. Proteolysis is a confounding factor in the interpretation of faecal calprotectin
  15. Urinary neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic kidney disease patients
  16. Cancer Diagnostics
  17. Quantification of adult T-cell leukemia/lymphoma cells using simple four-color flow cytometry
  18. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development
  19. Cardiovascular Diseases
  20. Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease
  21. S100B concentrations increase perioperatively in jugular vein blood despite limited metabolic and inflammatory response to clinically uneventful carotid endarterectomy
  22. Long-term biological variability of galectin-3 after heart transplantation
  23. Diabetes
  24. Evaluation of a next generation direct whole blood enzymatic assay for hemoglobin A1c on the ARCHITECT c8000 chemistry system
  25. The 13C-glucose breath test is a valid non-invasive screening tool to identify metabolic syndrome in adolescents
  26. Comparison of a direct enzymatic assay and polyacrylamide tube gel electrophoresis for measurement of small, dense low-density lipoprotein cholesterol
  27. Letters to the Editor
  28. Comparison of Abbott Architect high-sensitivity troponin I in Rapid Serum Tubes and plasma
  29. Can EDTA, EDTA-fluoride, and buffered citrate tubes be used for measurement of HbA1c on the Bio-Rad D10?
  30. How to reduce EDTA contamination in laboratory specimens: a Tunisian experience
  31. Does mean platelet volume share any relationship with biochemical and hematological parameters?
  32. Association of retrospective markers of glycemia and the use of continuous glucose monitoring in white adults with type 2 diabetes mellitus – a preliminary report
  33. Operative performances and efficiency for infectious disease testing of two immunochemistry analyzers – Abbott ARCHITECT i2000SR and DiaSorin Liaison XL
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 3.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-0427/html
Button zum nach oben scrollen